Class 1 recall due to damage to distal catheter shaft and risk of air embolism and myocardial infarction.
Continue reading...30. July 2009
Comments Off
Two previously uncharacterized safety concerns associated with the use of colchicine.
Continue reading...28. July 2009
Comments Off
Products are unapproved drugs and associated with serious risks of liver injury, stroke.
Continue reading...22. July 2009
Comments Off
FDA analysis has found carcinogens and toxic chemicals such as diethylene glycol, an ingredient used in antifreeze.
Continue reading...18. July 2009
Comments Off
Nationwide recall due to potential bacterial contamination, placing children with weakened immune systems at risk of harm.
Continue reading...17. July 2009
Comments Off
Recall due to presence of elevated endotoxin levels in some vials.
Continue reading...17. July 2009
Comments Off
Products recalled due to an undeclared drug ingredient which may present a significant health risk for patients with history of coronary artery disease, congestive heart failure, arrhythmias or stroke. Posted 07/17/2009
Continue reading...16. July 2009
Comments Off
FDA is evaluating interim safety findings from an ongoing study of Xolair (omalizumab) that suggests an increased number of cardiovascular and cerebrovascular adverse events.
Continue reading...16. July 2009
Comments Off
Products recalled because samples were found to contain undeclared drug ingredients.
Continue reading...15. July 2009
Comments Off
Nationwide voluntary recall of all lots of Brookstone Pharmaceuticals' Concentrated Acetaminophen Drops in 16 ounce (473 ml) bulk containers, a cautionary measure to minimize any confusion and potential risk to patients from dosing errors.
Continue reading...
30. July 2009
Comments Off